PRNewsWire
15 Jul 2026, 11:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Intensity Therapeutics has restarted patient dosing in its Phase 2 INVINCIBLE-4 study for triple-negative breast cancer (TNBC). — Resuming a clinical trial after a pause is a positive regulatory and operational milestone that keeps the lead candidate's development timeline alive.
+0.40The INVINCIBLE-4 study was previously paused to evaluate skin irritation issues observed in some patients. — A safety-related pause indicates a potential risk in the drug's delivery or toxicity profile, though the restart suggests the issue was manageable.
-0.30Early data from 14 patients showed a favorable trend toward fewer grade 3 or higher adverse events for those receiving INT230-6 compared to standard-of-care alone. — Positive early safety and tolerability signals are crucial for a drug intended to be used in combination with harsh chemotherapy.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
The company modified the trial protocol to use a lower drug-to-tumor volume ratio and a single injection of INT230-6 to address safety concerns. — Protocol amendments are common in Phase 2; while it shows a reaction to adverse events, it demonstrates a proactive path to continuing the trial.
+0.10Which stocks this story touches
The company has restarted a Phase 2 clinical trial for its lead candidate and reported a favorable trend in early safety data.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Reuters
1h ago
